News Summary: Merck suspends Tredaptive sales

Published



SUSPECT MEDICINE: Merck & Co. is suspending sales of the cholesterol drug Tredaptive after initial results from a study showed that it wasn’t effective and could raise the risk of some serious side effects.

WHO’S AFFECTED: The tablets aren’t approved in the United States, but they are sold in about 40 countries, including in Europe.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.